Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Xeris Pharmaceuticals
Xeris Pharmaceuticals
(XERS)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
*Quarterly sales USD (in millions)
Mock data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Keveyis
Dichlorphenamide
1982-01-01
Glaucoma
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Glucagon
congenital hyperinsulinism
,
nesidioblastosis
,
diabetes mellitus
,
hyperinsulinism
,
hypoglycemia
,
type 1 diabetes mellitus
Sodium chloride
dermatomyositis
,
systemic scleroderma
,
diffuse scleroderma
,
sclerosis
,
diabetes mellitus
,
type 1 diabetes mellitus
,
leukemia
,
myelodysplastic syndromes
,
non-hodgkin lymphoma
,
bcr-abl positive chronic myelogenous leukemia
,
hodgkin disease
,
chronic kidney failure
,
lupus nephritis
,
nephritis
,
rheumatoid arthritis
,
psoriasis
,
arthritis
,
colorectal neoplasms
,
covid-19
,
psoriatic arthritis
,
breast neoplasms
,
hematologic neoplasms
,
bone fractures
,
graves ophthalmopathy
,
eye diseases
,
thyroid diseases
,
neoplasm metastasis
,
chronic renal insufficiency
,
kidney diseases
,
hyperparathyroidism
,
secondary hyperparathyroidism
,
cardiovascular diseases
,
atherosclerosis
Insulin
healthy volunteers/patients
,
renal insufficiency
,
critical illness
,
parkinson disease
,
fibrosis
,
cystic fibrosis
,
sepsis
,
pituitary dwarfism
,
dwarfism
,
cardiovascular diseases
,
asthma
,
leukemia
,
lymphoma
,
precursor cell lymphoblastic leukemia-lymphoma
,
lymphoid leukemia
,
chronic obstructive pulmonary disease
,
lung diseases
,
obstructive lung diseases
,
gestational diabetes
,
nutrition disorders
,
cardiac surgical procedures
,
septic shock
,
shock
,
toxemia
,
diabetes mellitus
,
type 2 diabetes mellitus
,
type 1 diabetes mellitus
,
drug delivery systems
,
hypoglycemia
,
obesity
,
overweight
,
hyperglycemia
,
insulin resistance
,
body weight changes
,
atherosclerosis
,
arteriosclerosis
,
emergencies
,
inflammation
,
ketosis
,
acidosis
,
diabetic ketoacidosis
,
chronic renal insufficiency
,
kidney diseases
,
respiratory insufficiency
,
surgical wound infection
,
latent autoimmune diabetes in adults
,
weight loss
,
heart disease risk factors
,
hemostasis
,
patient participation
Viaject
type 1 diabetes mellitus
,
peripheral nervous system diseases
,
diabetic neuropathies
,
type 2 diabetes mellitus
,
diabetes mellitus
,
insulin resistance
,
metabolic syndrome
,
dyslipidemias
,
hypersensitivity
,
hiv infections
,
acquired immunodeficiency syndrome
,
hypertriglyceridemia
,
angina pectoris
,
stable angina
,
postpartum depression
,
abdominal obesity
,
lipid metabolism
,
latent autoimmune diabetes in adults
,
inflammation
Pram9
diabetes mellitus
,
type 1 diabetes mellitus
Pancreatin
type 1 diabetes mellitus
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use